The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Prolactin Levels and Adverse Events in Patients Treated with Risperidone
Abstract
Hyperprolactinemia is a common clinical disorder that may lead to sexual dysfunction or galactorrhea. It may arise from a variety of etiologies, including the use of antipsychotic agents, presumably because of a dopamine receptor blockade. This analysis was designed to characterize the relationship between risperidone, serum prolactin levels, and possible clinical sequelae. All data from randomized, double-blind studies of risperidone in patients with chronic schizophrenia were analyzed. The two largest studies (the North American and multinational trials) included 841 patients (259 women, 582 men) with paired prolactin level data and 1,884 patients (554 women, 1,330 men) with data on six adverse events possibly associated with increased prolactin levels (amenorrhea, galactorrhea, and decreased libido in women; erectile dysfunction, ejaculatory dysfunction, gynecomastia, and decreased libido in men). Both risperidone and haloperidol produced dose-related increases in plasma prolactin levels in men and women. Among women, the risperidone dose was not correlated with adverse events, nor were the adverse events correlated with endpoint prolactin levels. Among men, the incidence of adverse events was positively correlated with risperidone dose; however, at risperidone doses of 4 to 10 mg/day the incidence of adverse events was not significantly higher than that observed in patients receiving placebo. Furthermore, adverse events in men were unrelated to plasma prolactin levels. Risperidone-associated increase in serum prolactin levels was not significantly correlated to the emergence of possible prolactin-related side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Multiple receptors for dopamine
Kebabian, J. W., & Calne, D. B. (1979) · Nature · doi:10.1038/277093a0 · Cited by 3,725
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Postmenopausal Hormone Therapy and Mortality
Grodstein, F., Stampfer, M. J., Colditz, G. A., Willett, W. C., Manson, J. E., Joffe, M., Rosner, B., Fuchs, C., Hankinson, S. E., Hunter, D. J., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706193362501 · Cited by 1,184
CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MacEWAN, G. W., LABELLE, A., BEAUCLAIR, L., & ARNOTT, W. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 778
Peuskens, J. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.6.712 · Cited by 551
Wang, C. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.10.3654 · Cited by 261
CHLORPROMAZINE STIMULATION AND L-DOPA SUPPRESSION OF PLASMA PROLACTIN IN MAN1
Kleinberg, D. L., Noel, G. L., & Frantz, A. G. (1971) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-33-5-873 · Cited by 175
Self-citationProgressive trabecular osteopenia in women with hyperprolactinemic amenorrhea
Biller, B. M. K., Baum, H. B. A., Rosenthal, D. I., SAXE, V. C., Charpie, P. M., & Klibanski, A. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.3.1517356 · Cited by 146
Cited by
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Self-citationModern antipsychotic drugs: a critical overview
Gardner, D. M. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041064 · Cited by 422
Metadata
- Authors
- Kleinberg, D. L., Davis, J. M., de Coster, R., Van Baelen, B., & Brecher, M.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1999-02
- Volume
- 19
- Issue
- 1
- Pages
- 57-61
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2015837785
- Cited by
- 307
- References
- 14
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prolactin Levels and Adverse Events in Patients Treated with Risperidone. https://app.cochat.ai/papers/10.1097/00004714-199902000-00011
- The paper
- Kleinberg, D. L., Davis, J. M., de Coster, R., Van Baelen, B., & Brecher, M. (1999). Prolactin Levels and Adverse Events in Patients Treated with Risperidone. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199902000-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.